Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression

Integrating Tissue-based Spatial Information to Elucidate How Obesity-induced Tumour Metabolites Drive Prostate Cancer Progression

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06292897

Acronym

OBESITA'&PCa

Enrollment

Registered

2024-03-05

Start date

2023-03-20

Completion date

2027-01-15

Last updated

2024-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Prostate Adenocarcinoma, Prostate Cancer, Prostate Neoplasm, Prostatic Neoplasm

Brief summary

Evaluate the protein expression of lactate dehydrogenase enzyme (LDHA) and MCT-1/-4 transporters, involved in lactate synthesis and transport, in prostate carcinoma tissues from severely overweight/obese (BMI \> 27.5) and non-severely overweight/normoweight (BMI \< 27.5) patients affected by prostate carcinoma. ii. Characterize the immune infiltrate in the prostate carcinoma of the aforementioned patients. iii. Assess the association between intra-tumoral lactate accumulation (using LDHA and MCT-4 protein expression levels as readouts) and alterations in the tumor immune microenvironment and/or deregulation of relevant oncogenic pathways.

Interventions

OTHERobservational study

observational study

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* affected by prostate cancer

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Assess the protein expression of LDHA enzyme and MCT-1/-4 transporters in prostate carcinoma	4 years

Countries

Italy

Contacts

Primary ContactGiancarlo Albo, MD,

giancarlo.albo@policlinico.mi.it00390255034501

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026